MAM
AMLX icon

Meeder Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Meeder Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-661
Closed -$9.19K – 934
2026
Q1 		$9.19K Sell
661
-1,438
-69% -$20.2K ﹤0.01% 714
2025
Q4 		$25.4K Buy
+2,099
New +$28.5K ﹤0.01% 493

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Meeder Asset Management's AMLX Position: Q2 2026 in Review

Meeder Asset Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2026, closing a stake of 661 shares — an estimated $9.19K sold.

Meeder Asset Management first reported a position in AMLX in Q4 2025 and held it in 2 quarters. The position peaked at $25.4K in Q4 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Meeder Asset Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Meeder Asset Management sold 661 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $9.19K.
  • Meeder Asset Management first reported a position in Amylyx Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Meeder Asset Management's Amylyx Pharmaceuticals position peaked at $25.4K in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.